INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 169 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,580,924 | -99.4% | 85,271 | -95.8% | 0.03% | -98.5% |
| Q2 2017 | $246,449,000 | +7.4% | 2,035,592 | +0.4% | 2.00% | +13.7% |
| Q1 2017 | $229,389,000 | +4.4% | 2,028,192 | +0.3% | 1.76% | +3.0% |
| Q4 2016 | $219,776,000 | -33.7% | 2,022,792 | +0.4% | 1.71% | -31.1% |
| Q3 2016 | $331,680,000 | +16.6% | 2,015,192 | +1.1% | 2.48% | +1.8% |
| Q2 2016 | $284,446,000 | +32.8% | 1,993,592 | +19.6% | 2.44% | +16.7% |
| Q1 2016 | $214,126,000 | +8.6% | 1,666,737 | +26.3% | 2.09% | -3.9% |
| Q4 2015 | $197,125,000 | -9.9% | 1,319,887 | +0.0% | 2.17% | -21.8% |
| Q3 2015 | $218,853,000 | -31.6% | 1,319,507 | -0.4% | 2.78% | -2.8% |
| Q2 2015 | $319,734,000 | -16.0% | 1,324,607 | -1.8% | 2.85% | -15.3% |
| Q1 2015 | $380,554,000 | +70.3% | 1,349,387 | -5.8% | 3.37% | +65.3% |
| Q4 2014 | $223,403,000 | -29.1% | 1,432,071 | +7.6% | 2.04% | -24.4% |
| Q3 2014 | $314,920,000 | +33.0% | 1,330,516 | +33.0% | 2.70% | +45.5% |
| Q2 2014 | $236,766,000 | – | 1,000,576 | – | 1.85% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |